Non-Hodgkin Lymphoma | Specialty

The OncLive Non-Hodgkin Lymphoma condition center page is a comprehensive resource for clinical news and expert insights on various types of non-Hodgkin lymphoma, including diffuse large B-cell lymphoma, follicular lymphoma, chronic lymphocytic leukemia, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in non-Hodgkin lymphoma.

FDA Awards Acalabrutinib Priority Review in MCL

August 2nd 2017

The FDA has granted a priority review to a new drug application for acalabrutinib for patients with previously-treated mantle cell lymphoma.

FDA Grants Acalabrutinib Breakthrough Designation in MCL

August 2nd 2017

The FDA has granted acalabrutinib a breakthrough therapy designation for patients with previously-treated mantle cell lymphoma.

EU Approval Sought for Axicabtagene Ciloleucel in Non-Hodgkin Lymphoma

August 1st 2017

Kite Pharma has submitted a Marketing Authorization Application to the European Medicines Agency for axicabtagene ciloleucel (axi-cel) to treat 3 forms of non-Hodgkin lymphoma.

CD19 CAR T-Cell Therapy Active in Ibrutinib-Refractory CLL

July 31st 2017

Treatment with CD19 chimeric antigen receptor-modified T-cell therapy induced a high response rate in patients with high-risk, ibrutinib-refractory chronic lymphocytic leukemia.

Emerging Agents for Mantle Cell Lymphoma

July 26th 2017

Acalabrutinib for Treating Mantle Cell Lymphoma

July 26th 2017

Ongoing Challenges in Treating Mantle Cell Lymphoma

July 26th 2017

Treating Relapsed/Refractory Mantle Cell Lymphoma

July 26th 2017

Role of Maintenance Therapy in Mantle Cell Lymphoma

July 26th 2017

Response Assessment in Mantle Cell Lymphoma

July 26th 2017

Options for Upfront Therapy in MCL

July 26th 2017

Induction Therapy for MCL

July 26th 2017

Risk Assessment and Prognosis in MCL

July 26th 2017

Biology of Mantle Cell Lymphoma

July 26th 2017

Mantle Cell Lymphoma: Evolution of Therapy

July 26th 2017

Axicabtagene Ciloleucel Emerges as Potential Standard for Some NHL Patients

July 25th 2017

Sattva S. Neelapu, MD, discusses the latest results for axicabtagene ciloleucel (KTE-C19) for transplant-ineligible patients with relapsed/refractory non-Hodgkin lymphoma and the CAR T-cell therapy’s potential to be a new standard of care.

Expert Discusses Pembrolizumab Plus Rituximab in Follicular Lymphoma

July 25th 2017

Loretta Nastoupil, MD, discusses the positive interim analysis and shared her thoughts on areas of future investigation for patients with relapsed follicular lymphoma.

Frontline Obinutuzumab Recommended for EU Approval for Follicular Lymphoma

July 21st 2017

The European Medicines Agency's Committee for Medicinal Products for Human Use has recommended approval of obinutuzumab in the frontline setting for the treatment of patients with follicular lymphoma.

Dr. Matasar on Antibody-Drug Conjugates in B-Cell Malignancies

July 14th 2017

Matthew J. Matasar, MD, attending physician, Memorial Sloan Kettering Cancer Center, discusses antibody drug conjugates in B-cell malignancies.

Dr. Tilly Discusses Study of POLA-R-CHP in DLBCL

July 12th 2017

Herve Tilly, MD, PhD, Centre Henri Becquerel, discusses a study of polatuzumab vedotin combined with rituximab (Rituxan), cyclophosphamide, doxorubicin and prednisone (PLOA-R-CHP) in patients with previously untreated diffuse large B-cell lymphoma.